Record mula sa primary source

MateryalTopline na resulta

Lexeo LX2020 Phase 1/2 HEROIC-PKP2 shows 80% NSVT reduction; FDA open to surrogate for accelerated approval

Interim Phase 1/2 data reported positive reductions in NSVT and PVC burden plus cardiac function improvements. FDA open to NSVT as primary surrogate endpoint for accelerated approval. Pivotal study design finalization expected in H1 2027 with study initiation in H2 2027.

Mahahalagang fact

Na-file
Okt 15, 2026, 12:00 PM
Kaganapan
Topline na resulta
Direksyon
Positibo
Asset
LX2020
Pinagmulan
SEC 8-K
Kumpiyansa
May source
Mga kalahok
10 (7 mataas na dosis)
Pagbaba ng PVC
44% average na pagbaba (mataas na dosis)
Pagbaba ng NSVT
80% average na pagbaba (mataas na dosis)

Sipi mula sa source

EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020 generally well tolerated across 10 participants with no clinically significant complement activation U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 Cash, cash equivalents and investments of $219.1 million expected to provide oper

SEC 8-K

Lexeo LX2020 Phase 1/2 HEROIC-PKP2 shows 80% NSVT reduction; FDA open to surrogate for accelerated approval | SimianX AI